Lv1
30 积分 2023-02-08 加入
A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity
1个月前
已完结
Monitoring Compound-Related Effects on Coagulability in Rats and Cynomolgus and Rhesus Monkeys by Thrombin Generation Kinetic Measurement
1个月前
已完结
Interleukin (IL) 31 induces in cynomolgus monkeys a rapid and intense itch response that can be inhibited by an IL‐31 neutralizing antibody
4个月前
已完结
A Mouse Model of MC903‐Induced Atopic Dermatitis
4个月前
已完结
Sophocarpine alleviates chronic itch in mouse atopic dermatitis by inhibiting spinal astrocyte reactivity and pro-inflammatory signaling
4个月前
已完结
TMEM232 promotes the inflammatory response in atopic dermatitis via the nuclear factor-κB and signal transducer and activator of transcription 3 signalling pathways
4个月前
已完结
IRAK4 inhibition dampens pathogenic processes driving inflammatory skin diseases
4个月前
已完结
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
5个月前
已完结
OP0079 Clinical, Cellular Kinetics, Pharmacodynamics and Biomarker Data Up to 12 Months After YTB323 (Rapcabtagene Autoleucel), a Rapidly Manufactured CD19 CAR-T Therapy, From an Open-Label, Phase 1/2 Study in Severe Refractory SLE
6个月前
已关闭
OP0089 PHASE 2 SAFETY AND EFFICACY OF SUBCUTANEOUS (S.C.) DOSE IANALUMAB (VAY736; ANTI-BAFFR mAb) ADMINISTERED EVERY 4 WEEKS UP TO 48 WEEKS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
6个月前
已关闭
皖公网安备34019202002308
